Find Dofetilide manufacturers, exporters & distributors on PharmaCompass

Dofetilide

Farmak Dofetilide

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

With Fermion, start the journey of your innovative API.

Contact Supplier

Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

18 API Suppliers, 13 USDMF, 2 EU WC, 10 NDC API, 8 Listed Suppliers, $ API Reference Price

18 API Suppliers
13 USDMF
2 EU WC
10 NDC API
8 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

5 Intermediates Suppliers

5 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

52 FDF Dossiers, 42 FDA Orange Book, 3 Europe, 7 Listed Dossiers

52 FDF Dossiers
42 FDA Orange Book
3 Europe
7 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 0.125MG, CAPSULE;ORAL - 0.25MG, CAPSULE;ORAL - 0.5MG

drugProductComposition
CAPSULE;ORAL - 0.125MG
CAPSULE;ORAL - 0.25MG
CAPSULE;ORAL - 0.5MG

RELATED EXCIPIENT COMPANIES

4 SPI Pharma, 8 DKSH, 2 Faran Shimi Pharmaceutical, 9 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 4 ACG Worldwide, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 BASF, 2 DFE Pharma, 1 Finar, 5 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 4 Kerry, 3 Lonza Capsugel, 7 Microlex e.U, 1 Pharmatrans-Sanaq, 2 Pluviaendo, 2 Prachin Chemical, 1 Qualicaps, 15 Roquette, 2 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 8 Sigachi Industries, 1 Valens Pharmachem, 2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

37 Fillers, Diluents & Binders, 19 Direct Compression, 17 Thickeners and Stabilizers, 11 Lubricants & Glidants, 11 Co-Processed Excipients, 9 Coating Systems & Additives, 9 Disintegrants & Superdisintegrants, 8 Empty Capsules, 6 Granulation, 6 Taste Masking, 5 Film Formers & Plasticizers, 5 Controlled & Modified Release, 5 Chewable & Orodispersible Aids, 4 Emulsifying Agents, 3 Coloring Agents, 3 Topical, 2 Solubilizers, 1 Parenteral, 1 API Stability Enhancers, 1 Rheology Modifiers

DIGITAL CONTENT

16 NEWS #PharmaBuzz

media
16 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 3 Finished Drug Prices, 2 Annual Reports

globalSalesInformation
2 US Medicaid Prescriptions
3 Finished Drug Prices
2 Annual Reports

MARKET PLACE

1 APIs

marketPlace
1 APIs

REF. STANDARDS & IMPURITIES

2 USP , 2 Others

otherSolutions
2 USP
2 Others

Dofetilide

Synopsis

ACTIVE PHARMA INGREDIENTS

18

API Suppliers

13

USDMF

0

CEP/COS

CEP/COS Certifications

0

JDMF

2

EU WC

0

KDMF

10

NDC API

0

VMF

8

Listed Suppliers

API REF. PRICE (USD/KG)

$

$ 386,113

MARKET PLACE

1

API

0

FDF

5INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

52

FDF Dossiers

42

FDA Orange Book

FDA (Orange Book)

3

Europe

0

Canada

0

Australia

0

South Africa

7

Listed Dossiers

1DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

2

USP

0

JP

2

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

16

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

82,188,795

Annual Reports (USD Million)

294

Finished Drug Prices

95 RELATED EXCIPIENT COMPANIES

163EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Click the button for full data set

Also known as: 115256-11-6, Tikosyn, Dofetilida, Dofetilidum, Dofetilidum [inn-latin], Dofetilida [inn-spanish]

Molecular Formula

C₁₉H₂₇N₃O₅S₂

Molecular Weight

441.6 g/mol

InChI Key

IXTMWRCNAAVVAI-UHFFFAOYSA-N

FDA UNII

R4Z9X1N2ND

Dofetilide

Dofetilide is a sulfonamide class III antiarrhythmic agent and potassium channel blocker. Dofetilide selectively blocks cardiac ion channels of the rapid component of the delayed rectifier potassium current Ikr. This antiarrhythmic agent prolongs cardiac action potential duration and effective refractory period due to delayed repolarization without affecting conduction velocity. This results in a normal sinus rhythm. Dofetilide is used in the treatment of atrial fibrillation and flutter.

Dofetilide is an Antiarrhythmic.

1 2D Structure

Dofetilide

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide

2.1.2 InChI

InChI=1S/C19H27N3O5S2/c1-22(13-12-16-4-6-17(7-5-16)20-28(2,23)24)14-15-27-19-10-8-18(9-11-19)21-29(3,25)26/h4-11,20-21H,12-15H2,1-3H3

2.1.3 InChI Key

IXTMWRCNAAVVAI-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C

2.2 Other Identifiers

2.2.1 UNII

R4Z9X1N2ND

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 1-(4-methanesulfonamidophenoxy)-2-(n-(4-methanesulfonamidophenethyl)-n-methylamine)ethane

2. 1-mspmpe

3. Tikosyn

4. Uk 68798

5. Uk-68,798

2.3.2 Depositor-Supplied Synonyms

1. 115256-11-6

2. Tikosyn

3. Dofetilida

4. Dofetilidum

5. Dofetilidum [inn-latin]

6. Dofetilida [inn-spanish]

7. Uk 68798

8. Uk-68798

9. Uk-68,798

10. Dofetilide (tikosyn)

11. N-(4-(2-(methyl(2-(4-(methylsulfonamido)phenoxy)ethyl)amino)ethyl)phenyl)methanesulfonamide

12. Beta-((p-methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide

13. Chembl473

14. R4z9x1n2nd

15. N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide

16. Chebi:4681

17. 1-(4-methanesulphonamidophenoxy)-2-[n-(4-methanesulphonamidophenethyl)-n-methylamino]ethane

18. N-[4-[2-[methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]methanesulfonamide

19. Methanesulfonamide, N-[4-[2-[methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]-

20. Ncgc00164549-01

21. Uk 68789

22. Dsstox_cid_26433

23. Dsstox_rid_81610

24. Dsstox_gsid_46433

25. Methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl)-

26. Xelide

27. N-(4-{2-[methyl(2-{4-[(methylsulfonyl)amino]phenoxy}ethyl)amino]ethyl}phenyl)methanesulfonamide

28. Smr000466333

29. Tikosyn (tn)

30. Cas-115256-11-6

31. Uk 68,798

32. Unii-r4z9x1n2nd

33. Hsdb 7927

34. 1-(4-methanesulphonamidophenoxy)-2-(n-(4-methanesulphonamidophenethyl)-n-methylamino)ethane

35. Dofetilide [usan:usp:inn:ban]

36. Dofetilide- Bio-x

37. Uk68798

38. Dofetilide [mi]

39. Dofetilide [inn]

40. Dofetilide [jan]

41. Dofetilide [usan]

42. Dofetilide [vandf]

43. Dofetilide [mart.]

44. Dofetilide [usp-rs]

45. Dofetilide [who-dd]

46. Schembl16135

47. Dofetilide (jan/usp/inn)

48. Mls000759442

49. Mls001424185

50. Mls006010154

51. Dofetilide [ema Epar]

52. Gtpl2604

53. Dofetilide [orange Book]

54. Dofetilide, >=98% (hplc)

55. Dtxsid5046433

56. Dofetilide [usp Monograph]

57. Hms2051n14

58. Hms2089f03

59. Hms2232h19

60. Hms3261g03

61. Hms3370b18

62. Hms3393n14

63. Hms3655a17

64. Hms3715h20

65. Zinc596731

66. Act04222

67. Bcp04770

68. Hy-b0232

69. Tox21_112178

70. Tox21_500351

71. Ac-385

72. Bdbm50031720

73. Nsc786034

74. S1658

75. Akos005259921

76. Tox21_112178_1

77. Bcp9000619

78. Ccg-101037

79. Db00204

80. Nc00287

81. Nsc-786034

82. Uk68789

83. Mrf-0000317

84. N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methyl-amino]ethyl]phenyl]methanesulfonamide

85. Ncgc00164549-02

86. Ncgc00261036-01

87. Bd164377

88. Bcp0726000009

89. Db-041252

90. Ft-0631076

91. Sw197667-2

92. C07751

93. D00647

94. H11953

95. Ab00639976-06

96. Ab00639976-08

97. Ab00639976_09

98. 256d116

99. A803396

100. Sr-01000759368

101. J-003271

102. Q3712521

103. Sr-01000759368-4

104. Brd-k86887724-001-05-6

105. Dofetilide, United States Pharmacopeia (usp) Reference Standard

106. .beta.-((p-methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide

107. 1-(4-methansulphonamidophenoxy)-2-[n-(4-methanesulphonamidophenethyl)-n-methylamino]ethane

108. N-[4-[2-[2-(4-methanesulfonamidophenyl)ethyl-methylamino]ethoxy]phenyl]methanesulfonamide

109. (dofetilide) N-[4-(2-{[2-(4-methanesulfonylamino-phenyl)-ethyl]-methylamino}-ethoxy)-phenyl]-methanesulfonamide

110. N-[4-(2-{[2-(4-methanesulfonamidophenoxy)ethyl](methyl)amino}ethyl)phenyl]methanesulfonamide

111. N-[4-(2-{[2-(4-methanesulfonylamino-phenoxy)-ethyl]-methyl-amino}-ethyl)-phenyl]-methanesulfonamide

112. N-[4-(2-{[2-(4-methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide (dofetilide)

113. N-[4-(2-{[2-(4-methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide (uk-68798)

114. N-[4-(2-{[2-(4-methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide Dofetilide

115. N-[4-(2-{2-[4-(methanesulphonamido)phenoxyl]-n-methylethylamino}ethyl)phenyl]-methanesulphonamide

2.4 Create Date

2005-06-24

3 Chemical and Physical Properties

Molecular Formula	C₁₉H₂₇N₃O₅S₂
Molecular Weight	441.6 g/mol
XLogP3	1.8
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	11
Exact Mass	441.13921332 g/mol
Monoisotopic Mass	441.13921332 g/mol
Topological Polar Surface Area	122 Å²
Heavy Atom Count	29
Formal Charge	0
Complexity	672
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Information

1 of 2
Drug Name	Tikosyn
PubMed Health	Dofetilide (By mouth)
Drug Classes	Antiarrhythmic, Group III
Drug Label	TIKOSYN (dofetilide) is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties. Its empirical formula is C19H27N3O5S2 and it has a molecular weight of 441.6. The structural formula is The chemical name for d...
Active Ingredient	Dofetilide
Dosage Form	Capsule
Route	Oral
Strength	0.5mg; 0.25mg; 0.125mg
Market Status	Prescription
Company	Pfizer

2 of 2
Drug Name	Tikosyn
PubMed Health	Dofetilide (By mouth)
Drug Classes	Antiarrhythmic, Group III
Drug Label	TIKOSYN (dofetilide) is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties. Its empirical formula is C19H27N3O5S2 and it has a molecular weight of 441.6. The structural formula is The chemical name for d...
Active Ingredient	Dofetilide
Dosage Form	Capsule
Route	Oral
Strength	0.5mg; 0.25mg; 0.125mg
Market Status	Prescription
Company	Pfizer

4.2 Therapeutic Uses

Anti-Arrhythmia Agents, Potassium Channel Blockers

National Library of Medicine's Medical Subject Headings online file (MeSH, 2011)

Tikosyn is indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm. /Included in US product label/

US Natl Inst Health; DailyMed. Current Medication Information for TIKOSYN (dofetilide) capsule (April 2010). Available from, as of June 22, 2011: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17543&CFID=75477870&CFTOKEN=ffbdfdb0c7aeadf5-BC7DCA29-F9BA-036F-9F3757A5E6AB046F&jsessionid=ca304d974b4478175376

Tikosyn is indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter (AF/AFl)) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. Because Tikosyn can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic. /Included in US product label/

US Natl Inst Health; DailyMed. Current Medication Information for TIKOSYN (dofetilide) capsule (April 2010). Available from, as of June 22, 2011: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17543&CFID=75477870&CFTOKEN=ffbdfdb0c7aeadf5-BC7DCA29-F9BA-036F-9F3757A5E6AB046F&jsessionid=ca304d974b4478175376

4.3 Drug Warning

/BOXED WARNING/ To minimize the risk of induced arrhythmia, patients initiated or re-initiated on Tikosyn should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation ... . Tikosyn is available only to hospitals and prescribers who have received appropriate Tikosyn dosing and treatment initiation education;

US Natl Inst Health; DailyMed. Current Medication Information for TIKOSYN (dofetilide) capsule (Updated: February 2014). Available from, as of April 23, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02438044-d6a3-49e9-a1ac-3aad21ef2c8c

Tikosyn (dofetilide) can cause serious ventricular arrhythmias, primarily torsade de pointes (TdP) type ventricular tachycardia, a polymorphic ventricular tachycardia associated with QT interval prolongation. QT interval prolongation is directly related to dofetilide plasma concentration. Factors such as reduced creatinine clearance or certain dofetilide drug interactions will increase dofetilide plasma concentration. The risk of TdP can be reduced by controlling the plasma concentration through adjustment of the initial dofetilide dose according to creatinine clearance and by monitoring the ECG for excessive increases in the QT interval. Treatment with dofetilide must therefore be started only in patients placed for a minimum of three days in a facility that can provide electrocardiographic monitoring and in the presence of personnel trained in the management of serious ventricular arrhythmias. Calculation of the creatinine clearance for all patients must precede administration of the first dose of dofetilide.

US Natl Inst Health; DailyMed. Current Medication Information for TIKOSYN (dofetilide) capsule (April 2010). Available from, as of June 22, 2011: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17543&CFID=75477870&CFTOKEN=ffbdfdb0c7aeadf5-BC7DCA29-F9BA-036F-9F3757A5E6AB046F&jsessionid=ca304d974b4478175376

In patients with mild to moderate renal failure, decreases in dosage based on creatinine clearance are required to minimize the risk of torsades de pointes. The drug should not be used in patients with advanced renal failure or with inhibitors of renal cation transport.

Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill, 2006., p. 923

Torsades de pointes occurred in 1-3% of patients in clinical trials where strict exclusion criteria (e.g., hypokalemia) were applied and continuous ECG monitoring was used to detect marked QT prolongation in the hospital. The incidence of this adverse effect during more widespread use of the drug, marketed since 2000, is unknown. Other adverse effects were no more common than with placebo during premarketing clinical trials.

Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill, 2006., p. 923

For more Drug Warnings (Complete) data for Dofetilide (16 total), please visit the HSDB record page.

4.4 Drug Indication

For the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm

FDA Label

Tikosyn is a Class III antiarrhythmic agent that is indicated for the following:

- Conversion of persistent atrial fibrillation or atrial flutter to normal sinus rhythm in patients in whom cardioversion by electrical means is not appropriate and in whom the duration of the arrhythmic episode is less than 6 months (see section 5. 1).

- Maintenance of sinus rhythm (after conversion) in patients with persistent atrial fibrillation or atrial flutter. Because TIKOSYN can cause ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic and in whom other antiarrhythmic therapy is not appropriate.

Dofetilide has not been shown to be effective in patients with paroxysmal atrial arrhythmias (including paroxysmal atrial fibrillation).

5 Pharmacology and Biochemistry

5.1 Pharmacology

Dofetilide is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties and is indicated for the maintenance of normal sinus rhythm. Dofetilide increases the monophasic action potential duration in a predictable, concentration-dependent manner, primarily due to delayed repolarization. At concentrations covering several orders of magnitude, Dofetilide blocks only IKr with no relevant block of the other repolarizing potassium currents (e.g., IKs, IK1). At clinically relevant concentrations, Dofetilide has no effect on sodium channels (associated with Class I effect), adrenergic alpha-receptors, or adrenergic beta-receptors.

5.2 MeSH Pharmacological Classification

Potassium Channel Blockers

A class of drugs that act by inhibition of potassium efflux through cell membranes. Blockade of potassium channels prolongs the duration of ACTION POTENTIALS. They are used as ANTI-ARRHYTHMIA AGENTS and VASODILATOR AGENTS. (See all compounds classified as Potassium Channel Blockers.)

Anti-Arrhythmia Agents

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)

5.3 FDA Pharmacological Classification

5.3.1 Active Moiety

DOFETILIDE

5.3.2 FDA UNII

R4Z9X1N2ND

5.3.3 Pharmacological Classes

Antiarrhythmic [EPC]

5.4 ATC Code

C01BD04

C - Cardiovascular system

C01 - Cardiac therapy

C01B - Antiarrhythmics, class i and iii

C01BD - Antiarrhythmics, class iii

C01BD04 - Dofetilide

5.5 Absorption, Distribution and Excretion

Absorption

>90%

Volume of Distribution

3 L/kg

Approximately 80% of a single dose of dofetilide is excreted in urine, of which approximately 80% is excreted as unchanged dofetilide with the remaining 20% consisting of inactive or minimally active metabolites. Renal elimination involves both glomerular filtration and active tubular secretion (via the cation transport system, a process that can be inhibited by cimetidine, trimethoprim, prochlorperazine, megestrol and ketoconazole). ...

US Natl Inst Health; DailyMed. Current Medication Information for TIKOSYN (dofetilide) capsule (April 2010). Available from, as of June 22, 2011: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17543&CFID=75477870&CFTOKEN=ffbdfdb0c7aeadf5-BC7DCA29-F9BA-036F-9F3757A5E6AB046F&jsessionid=ca304d974b4478175376

The oral bioavailability of dofetilide is >90%, with maximal plasma concentrations occurring at about 2-3 hours in the fasted state. Oral bioavailability is unaffected by food or antacid. The terminal half life of Tikosyn is approximately 10 hours; steady state plasma concentrations are attained within 2-3 days, with an accumulation index of 1.5 to 2.0. Plasma concentrations are dose proportional. Plasma protein binding of dofetilide is 60-70%, is independent of plasma concentration, and is unaffected by renal impairment. Volume of distribution is 3 L/kg.

US Natl Inst Health; DailyMed. Current Medication Information for TIKOSYN (dofetilide) capsule (April 2010). Available from, as of June 22, 2011: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17543&CFID=75477870&CFTOKEN=ffbdfdb0c7aeadf5-BC7DCA29-F9BA-036F-9F3757A5E6AB046F&jsessionid=ca304d974b4478175376

1. Pharmacokinetics of dofetilide were studied in man, dog, rat and mouse after single IV and oral doses of dofetilide or (14)C-dofetilide. 2. Dofetilide was absorbed completely in all species. Low metabolic clearance in man resulted in complete bioavailability following oral administration. Higher metabolic clearance in rodents, and to a lesser extent dogs, resulted in decreased bioavailability because of first-pass metabolism. 3. Following IV administration, the volume of distribution showed only moderate variation in all species (2.8-6.3 l/kg). High plasma clearance in rodents resulted in short half-life values (mouse 0.32, male rat 0.5 and female rat 1.2 hr), while lower clearance in dog and man gave longer terminal elimination half-lives (4.6 and 7.6 hr respectively). 4. After single IV doses of (14)C-dofetilide, unchanged drug was the major component excreted in urine of all species with several metabolites also present. 5. Metabolites identified in urine from all species were formed by N-oxidation or N-dealkylation of the tertiary nitrogen atom of dofetilide. 6. After oral and IV administration of (14)C-dofetilide to man, parent compound was the only detectable component present in plasma and represented 75% of plasma radioactivity. No single metabolite accounted for greater than 5% of plasma radioactivity.

PMID:1441594 Smith DA et al; Xenobiotica 22 (6): 709-19 (1992)

5.6 Metabolism/Metabolites

Hepatic

Dofetilide, a class III antidysrhythmic agent, undergoes both renal and metabolic clearance. Characterization of the metabolism in vitro allows explanation of species differences, whereas identification of the human enzymes involved permits assessment of potential drug interaction. In liver microsomes, the rate of oxidative metabolism of dofetilide is in the order: male rat > female rat > dog > humans, which correlates with the metabolic clearance seen in vivo. In vitro products of oxidative metabolism, formed by N-dealkylation, are the same as those formed in vivo, with the N-desmethyl being the major product. This route of dofetilide metabolism is mediated by cytochrome P450 (CYP). In humans, N-demethylation has a high KM of 657 +/- 116 uM, indicating low affinity for the enzyme's active site. In a number of human liver microsomal preparations, this rate correlated (r = 0.903) with the activity of CYP3A4. There was no correlation with the activities of other isozymes. Specific isozyme inhibitors also indicated the involvement of CYP3A4, with partial inhibition being observed with ketoconazole and troleandeomycin, whereas the activator, alpha-naphthaflavone, caused increased turnover. No inhibition was observed with specific inhibitors or competing substrates for other isozymes. Dofetilide did not significantly inhibit CYP2C9, CYP2D6, or CYP3A4 at concentrations up to 100 microM in vitro. In contrast, amiodarone (IC50, 25 uM) and flecainide (49 microM) inhibited CYP2C9 and quinidine (0.26 uM), and flecainide (0.44 uM) inhibited CYP2D6. Many antidysrhythmic drugs have active, circulating metabolites, complicating the relationship of dose and clinical response. In vitro pharmacology studies allow assessment of the potential contribution to the pharmacological profile by metabolites. Potency of dofetilide and metabolites has been compared for class III (K+ channel blockade) and class I (Na+ channel blockade) antidysrhythmic activities. Three of the metabolites of dofetilide displayed class III activity but at concentrations at least 20-fold higher than dofetilide. Dofetilide N-oxide showed class I activity, but only at high concentration. Neither resting membrane potential or action potential amplitude were affected by any metabolite. This lack of biologically relevant activity is in accord with the close correlation between plasma concentrations of dofetilide and pharmacological response.

PMID:8801060 Walker DK et al; Drug Metab Dispos 24 (4): 447-55 (1996)

Approximately 80% of a single dose of dofetilide is excreted in urine, of which approximately 80% is excreted as unchanged dofetilide with the remaining 20% consisting of inactive or minimally active metabolites. ... In vitro studies with human liver microsomes show that dofetilide can be metabolized by CYP3A4, but it has a low affinity for this isoenzyme. Metabolites are formed by N-dealkylation and N-oxidation. There are no quantifiable metabolites circulating in plasma, but 5 metabolites have been identified in urine

US Natl Inst Health; DailyMed. Current Medication Information for TIKOSYN (dofetilide) capsule (April 2010). Available from, as of June 22, 2011: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17543&CFID=75477870&CFTOKEN=ffbdfdb0c7aeadf5-BC7DCA29-F9BA-036F-9F3757A5E6AB046F&jsessionid=ca304d974b4478175376

5.7 Biological Half-Life

10 hours

Following IV administration, ... high plasma clearance in rodents resulted in short half-life values (mouse 0.32, male rat 0.5 and female rat 1.2 hr), while lower clearance in dog and man gave longer terminal elimination half-lives (4.6 and 7.6 hr respectively). ...

PMID:1441594 Smith DA et al; Xenobiotica 22 (6): 709-19 (1992)

The terminal half life of Tikosyn is approximately 10 hours

US Natl Inst Health; DailyMed. Current Medication Information for TIKOSYN (dofetilide) capsule (April 2010). Available from, as of June 22, 2011: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17543&CFID=75477870&CFTOKEN=ffbdfdb0c7aeadf5-BC7DCA29-F9BA-036F-9F3757A5E6AB046F&jsessionid=ca304d974b4478175376

5.8 Mechanism of Action

The mechanism of action of Dofetilide is a blockade of the cardiac ion channel carrying the rapid component of the delayed rectifier potassium current, IKr. This inhibition of potassium channels results in a prolongation of action potential duration and the effective refractory period of accessory pathways (both anterograde and retrograde conduction in the accessory pathway).

Rapidly activating delayed rectifier current (IKr) is the key target of class III antiarrhythmic drugs including dofetilide. Due to its complex gating properties, the precise channel state or states that interact with these agents remain poorly defined. We have undertaken a careful analysis of the state dependence of HERG channel block by dofetilide in Xenopus oocytes and Chinese Hamster Ovary (CHO) cells by devising a protocol in which brief sampling pulses were superimposed over a wide range of test potentials. The rate of block onset, maximal steady-state block and IC50 were similar for all test potentials over the activation range, demonstrating that the drug probably interacts with open and/or inactivated but not resting HERG channels with high affinity. Reducing the fraction of inactivated channels at 0 mV by augmenting the external potassium concentration did not alter the sensitivity to dofetilide. In contrast, the S631A and S620T HERG mutations both eliminated inward rectification and reduced dofetilide affinity by approximately 10- and approximately 100-fold respectively. We have also found a novel ultra-slow activation process which occurs in wild type HERG channels at threshold potentials. Overall, ... data imply that dofetilide block occurs equally at all voltages positive to the activation threshold, and that the drug interacts with HERG channels in both the open and inactivated states.

PMID:11907818 Weerapura M et al; Pflugers Arch 443 (4): 520-31 (2002)

Tikosyn (dofetilide) shows Vaughan Williams Class III antiarrhythmic activity. The mechanism of action is blockade of the cardiac ion channel carrying the rapid component of the delayed rectifier potassium current, IKr. At concentrations covering several orders of magnitude, dofetilide blocks only IKr with no relevant block of the other repolarizing potassium currents (e.g., IKs, IK1). At clinically relevant concentrations, dofetilide has no effect on sodium channels (associated with Class I effect), adrenergic alpha-receptors, or adrenergic beta-receptors.

US Natl Inst Health; DailyMed. Current Medication Information for TIKOSYN (dofetilide) capsule (April 2010). Available from, as of June 22, 2011: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=17543&CFID=75477870&CFTOKEN=ffbdfdb0c7aeadf5-BC7DCA29-F9BA-036F-9F3757A5E6AB046F&jsessionid=ca304d974b4478175376

The human ether-a-go-go-related gene (HERG) encodes a K+ channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier K+ current (IKr). HERG/IKr channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic methanesulfonanilide drugs, such as dofetilide, E4031, and MK-499, at submicromolar concentrations. By contrast, the closely related bovine ether-a-go-go channel (BEAG) is 100-fold less sensitive to dofetilide. To identify the molecular determinants for dofetilide block, we first engineered chimeras between HERG and BEAG and then used site-directed mutagenesis to localize single amino acid residues responsible for block. Using constructs heterologously expressed in Xenopus oocytes, we found that transplantation of the S5-S6 linker from BEAG into HERG removed high-affinity block by dofetilide. A point mutation in the S5-S6 linker region, HERG S620T, abolished high-affinity block and interfered with C-type inactivation. Thus, our results indicate that important determinants of dofetilide binding are localized to the pore region of HERG. Since the loss of high-affinity drug binding was always correlated with a loss of C-type inactivation, it is possible that the changes observed in drug binding are due to indirect allosteric modifications in the structure of the channel protein and not to the direct interaction of dofetilide with the respective mutated site chains. However, the chimeric approach was not able to identify domains outside the S5-S6 linker region of the HERG channel as putative candidates involved in drug binding. Moreover, the reverse mutation BEAG T432S increased the affinity of BEAG K+ channels for dofetilide, whereas C-type inactivation could not be recovered. Thus, the serine in position HERG 620 may participate directly in dofetilide binding; however, an intact C-type inactivation process seems to be crucial for high-affinity drug binding.

PMID:9486667 Ficker E et al; Circ Res 82 (3): 386-9 (1998)

API SUPPLIERS

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

[{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1639679400,"product":"DOFETILIDE ( RE-IMPORT FOR REPROCESS & RE-EXPORT VIDE SB NO.7081341 DT.09.12.2020)","address":"43-11-56, SUBBALAKSHMI NAGAR,RAILW AY NEW COLONY","city":"VISAKHAPATNAM,ANDHRA PRADESH","supplier":"BIOPHORE INDIA PHARMACEUTICALS PVT LTD","supplierCountry":"INDIA","foreign_port":"N\/A","customer":"SIONC PHARMACEUTICALS","customerCountry":"INDIA","quantity":"2.74","actualQuantity":"2.74","unit":"KGS","unitRateFc":"15000","totalValueFC":"42039.3","currency":"USD","unitRateINR":"1157250","date":"17-Dec-2021","totalValueINR":"3170865","totalValueInUsd":"42039.3","indian_port":"HYDERABAD AIR","hs_no":"29332990","bill_no":"6722084","productDescription":"Re-export","marketType":"REGULATED MARKET","country":"INDIA","selfForZScoreResived":"Pharma Grade","supplierPort":"N\/A","supplierAddress":"","customerAddress":"43-11-56, SUBBALAKSHMI NAGAR,RAILW AY NEW COLONY"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1644431400,"product":"DOFETILIDE (QTY:1X0.1 GMS,PRICE: USD 23.73)(FOC)","address":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,","city":"TURKAPALLY-V SHAMIRPET HYDERABAD,TE","supplier":"UNITED STATES PHARMACOPEIAL ","supplierCountry":"UNITED STATES","foreign_port":"NA","customer":"UNITED STATES PHARMACOPEIA - INDIA PRIVATE LIMITED","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.0001","unit":"KGS","unitRateFc":"237300","totalValueFC":"24.5","currency":"USD","unitRateINR":"18360800","date":"10-Feb-2022","totalValueINR":"1836.08","totalValueInUsd":"24.5","indian_port":"HYDERABAD AIR","hs_no":"29359090","bill_no":"7430712","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1644431400,"product":"DOFETILIDE (QTY:1X0.35 GMS,PRICE: USD 60.42)(FOC)","address":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,","city":"TURKAPALLY-V SHAMIRPET HYDERABAD,TE","supplier":"UNITED STATES PHARMACOPEIAL ","supplierCountry":"UNITED STATES","foreign_port":"NA","customer":"UNITED STATES PHARMACOPEIA - INDIA PRIVATE LIMITED","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.00035","unit":"KGS","unitRateFc":"172628.6","totalValueFC":"62.4","currency":"USD","unitRateINR":"13356885.7","date":"10-Feb-2022","totalValueINR":"4674.91","totalValueInUsd":"62.4","indian_port":"HYDERABAD AIR","hs_no":"29359090","bill_no":"7430712","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1644431400,"product":"DOFETILIDE (QTY:1X0.4 GMS,PRICE: USD 67.76)(FOC)","address":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,","city":"TURKAPALLY-V SHAMIRPET HYDERABAD,TE","supplier":"UNITED STATES PHARMACOPEIAL ","supplierCountry":"UNITED STATES","foreign_port":"NA","customer":"UNITED STATES PHARMACOPEIA - INDIA PRIVATE LIMITED","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.0004","unit":"KGS","unitRateFc":"169400","totalValueFC":"69.9","currency":"USD","unitRateINR":"13107075","date":"10-Feb-2022","totalValueINR":"5242.83","totalValueInUsd":"69.9","indian_port":"HYDERABAD AIR","hs_no":"29359090","bill_no":"7430712","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1658428200,"product":"DOFETILIDE (QTY 1 X 200 MG PRICE: USD 767)(FOC)","address":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,","city":"TURKAPALLY-V SHAMIRPET HYDERABAD,TE","supplier":"USP","supplierCountry":"UNITED STATES","foreign_port":"NA","customer":"UNITED STATES PHARMACOPEIA - INDIA PRIVATE LIMITED","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.0002","unit":"KGS","unitRateFc":"3835000","totalValueFC":"799.7","currency":"USD","unitRateINR":"317965450","date":"22-Jul-2022","totalValueINR":"63593.09","totalValueInUsd":"799.7","indian_port":"HYDERABAD AIR","hs_no":"29359090","bill_no":"9674948","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1675967400,"product":"DOFETILIDE USP","address":"688, Ground Floor, 6th Main, III Block, Bel lay, Vidyaranyapura","city":"BANGALORE","supplier":"HYLORIS DEVELOPMENTS SA","supplierCountry":"BELGIUM","foreign_port":"NA","customer":"MAIVA PHARMA PRIVATE ","customerCountry":"INDIA","quantity":"0.03","actualQuantity":"30.5","unit":"GMS","unitRateFc":"200","totalValueFC":"6780.2","currency":"EUR","unitRateINR":"18360","date":"10-Feb-2023","totalValueINR":"559980","totalValueInUsd":"6780.2","indian_port":"BANGALORE AIR","hs_no":"29339990","bill_no":"4596882","productDescription":"API","marketType":"REGULATED MARKET","country":"BELGIUM","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"688, Ground Floor, 6th Main, III Block, Bel lay, Vidyaranyapura"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1679077800,"product":"DOFETILIDE USP, DOFETILIDE USP MECRONIZED DRUG SUBSTANCE","address":"688, Ground Floor, 6th Main, III Block, Bel lay, Vidyaranyapura","city":"BANGALORE","supplier":"HYLORIS DEVELOPMENTS SA","supplierCountry":"BELGIUM","foreign_port":"NA","customer":"MAIVA PHARMA PRIVATE ","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.78","unit":"GMS","unitRateFc":"200","totalValueFC":"169.5","currency":"EUR","unitRateINR":"17870","date":"18-Mar-2023","totalValueINR":"13938.6","totalValueInUsd":"169.5","indian_port":"BANGALORE AIR","hs_no":"29339990","bill_no":"5108440","productDescription":"API","marketType":"REGULATED MARKET","country":"BELGIUM","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"688, Ground Floor, 6th Main, III Block, Bel lay, Vidyaranyapura"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1697049000,"product":"DOFETILIDE (QTY: 1 X 200 MG, VALUE: USD 790) (FOC)","address":"P.NO. D6 D8, SY.NO. 234\/2,234\/3,","city":"TURKAPALLY(V),SHAMEERPET, HYDERABAD","supplier":"USP","supplierCountry":"CHINA","foreign_port":"WASHINGTON, DULLES I","customer":"UNITED STATES PHARMACOPEIA - INDIA PRIVATE LIMITED","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.0002","unit":"KGS","unitRateFc":"3950000","totalValueFC":"819.4","currency":"USD","unitRateINR":"341001700","date":"12-Oct-2023","totalValueINR":"68200.34","totalValueInUsd":"819.4","indian_port":"Hyderabad Air","hs_no":"29359090","bill_no":"8272075","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"WASHINGTON, DULLES I","supplierAddress":"7135 ENGLISH MUFFIN WAY FREDERICK,MD, US 21704, UNITED STATES OF AMERICA United States","customerAddress":"P.NO. D6 D8, SY.NO. 234\/2,234\/3,"}]

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country	Total Quantity (KGS)	Average Price (USD/KGS)	Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATES SUPPLIERS

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - CAPSULE;ORAL - 0.125MG

USFDA APPLICATION NUMBER - 20931

DOSAGE - CAPSULE;ORAL - 0.25MG

USFDA APPLICATION NUMBER - 20931

DOSAGE - CAPSULE;ORAL - 0.5MG

USFDA APPLICATION NUMBER - 20931

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

Direct Compression

Thickeners and Stabilizers

Lubricants & Glidants

Co-Processed Excipients

Coating Systems & Additives

Disintegrants & Superdisintegrants

Empty Capsules

Granulation

Taste Masking

Film Formers & Plasticizers

Controlled & Modified Release

Chewable & Orodispersible Aids

Emulsifying Agents

Coloring Agents

Topical

Solubilizers

Parenteral

API Stability Enhancers

Rheology Modifiers

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Finished Drug Prices

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

USP

Others

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Market Place

Home

Menu

Post Enquiry

Market Place

Search